UNSPSC 51182050: Metenolone acetate

This classification denotes an anabolic agent with the molecular formula C22H32O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W75590VPKQ, chemically known as androst-1-en-3-one, 17-(acetyloxy)-1-methyl-, (5.alpha.,17.beta.)-, but more generally known as metenolone acetate, which bears US NIH Compound Identifier 4088. European Medicines Agency schedules metenolone acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08823MIG.

Most nations, for tariff purposes, schedule metenolone acetate under HS 29372900. SMILES: CC1=CC(=O)C[C@H]2[C@]1([C@H]3CC[C@]4([C@H]([C@@H]3CC2)CC[C@@H]4OC(=O)C)C)C.

UNSPSC 51182050 Metenolone acetate is a Commodity code covering synthetic anabolic steroid pharmaceutical products. State and local governments procure these products primarily through multistate cooperative purchasing agreements that aggregate demand across participating jurisdictions and their healthcare facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, stands as a primary issuing body for this category, consolidating purchases across multiple states including Oregon. Procurement activity under this code targets manufacturers capable of supplying pharmaceuticals with specific National Drug Codes (NDCs), detailed product specifications, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), support electronic data interchange (EDI) capability, and offer flexible pricing formats including flat price, net price structures, or WAC-minus arrangements. Products must carry expiration dates of at least one year from manufacture with minimum six-month shelf life and comply with all FDA requirements.

The most recent solicitation activity centers in Minnesota and participating cooperative purchasing states. MMCAP issued an RFP (S1070000015802) on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026. Evaluation weighting emphasizes price competitiveness (75 percent) alongside administrative compliance and EDI capability (5 percent each), fixed pricing (10 percent), and administrative fee acceptance (5 percent). Awarded vendors face a two-year initial contract term with potential extensions, must carry $5 million commercial general liability insurance per occurrence, $2 million network security and privacy liability, and $2 million professional liability, and will incur performance penalties ranging from $200 to $1,500 per violation for reporting delays, missed onboarding, or improper class-of-trade denials. A 3 percent administrative fee applies to all contract purchases.